Arendt advises Alvotech on all Luxembourg law aspects with achieving triple-listed status following its listing on Nasdaq Stockholm

Experts involved in the Deal

Alvotech, a global biotech company specialising in the development and manufacture of biosimilar medicine, intends to list Swedish Depository Receipts (“SDRs”), equity share equivalents, on Nasdaq Stockholm, further expanding Alvotech’s development capabilities and establishing a footprint in the Swedish life science sector. Nasdaq Stockholm has assessed that Alvotech meets the applicable listing requirements, and that Nasdaq Stockholm will approve an application for admission to trading of the Company’s SDRs, subject to customary conditions. Alvotech has published a prospectus for the offering of SDRs (the “Offering”) on 8 May 2025 and the first day of trading on Nasdaq Stockholm is expected to be May 19, 2025.

Arendt has advised Alvotech on the Luxembourg capital markets, corporate and tax law aspects in connection with the Offering to the public in Sweden and the admission to trading of the SDRs on Nasdaq Stockholm. Arendt has played a key role in assisting Alvotech with the preparation of its prospectus and relevant corporate actions required, ensuring compliance and readiness for this significant milestone in which the company lists its shares on a third market (after Nasdaq US and Nasdaq Iceland).